Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTFQAYR)

• DTT Name: Cholesteryl ester transfer protein (CETP) DTT Info
• Gene Name: CETP

Molecule-Related Drug & Molecule List

7 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anacetrapib	DMP2BFG	Arteriosclerosis	BD40	Phase 3	[1]
Dalcetrapib	DMKNCVM	Acute coronary syndrome	BA41	Phase 3	[2]
Evacetrapib	DMCDZ15	Cardiovascular disease	BA00-BE2Z	Phase 3	[3]
DRL-17822	DMGD3XT	Arteriosclerosis	BD40	Phase 2	[3]
JTT-302	DMGLVBI	Lipid metabolism disorder	5C52.Z	Phase 2	[3]
TA-8995	DMAZHT0	Cardiovascular disease	BA00-BE2Z	Phase 2	[4]
BAY-60-5521	DMXIDWE	Arteriosclerosis	BD40	Phase 1	[5]

6 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CETi-1	DMUG5OB	Arteriosclerosis	BD40	Discontinued in Phase 2	[6]
Torcetrapib	DMDHYM7	Hyperlipidaemia	5C80	Discontinued in Phase 2	[7]
CP-800569	DMZ0YU7	Arteriosclerosis	BD40	Discontinued in Phase 1	[8]
DS-1442	DMS4IBW	Dyslipidemia	5C80-5C81	Discontinued in Phase 1	[9]
PF-3185043	DMCFYZM	Arteriosclerosis	BD40	Discontinued in Phase 1	[8]
R7232	DMETAP8	Dyslipidemia	5C80-5C81	Discontinued in Phase 1	[2]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAY-38-1315	DMVESTF	Arteriosclerosis	BD40	Preclinical	[10]

5 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NSC-40331	DMCFNMK	Discovery agent	N.A.	Investigative	[11]
NSC-89508	DMGS6HB	Discovery agent	N.A.	Investigative	[11]
SC-795	DMZN7YT	Discovery agent	N.A.	Investigative	[11]
TETRAHYDROQUINOLINE A	DMWRZJX	Discovery agent	N.A.	Investigative	[12]
TETRAHYDROQUINOLINE B	DMHT61V	Discovery agent	N.A.	Investigative	[12]

References

• [1] Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (C... Br J Clin Pharmacol. 2009 May;67(5):520-6.
• [2] Clinical pipeline report, company report or official report of Roche (2009).
• [3] The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8.
• [4] Amgen To Acquire Privately-Held Dezima Pharma
• [5] Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein. Br J Clin Pharmacol. 2012 Feb;73(2):210-8.
• [6] CETi-1. AVANT. Curr Opin Investig Drugs. 2004 Mar;5(3):334-8.
• [7] Safety and tolerability of dalcetrapib. Am J Cardiol. 2009 Jul 1;104(1):82-91.
• [8] Pfizer. Product Development Pipeline. March 31 2009.
• [9] Ds-1442b is a Novel, Potent Cetp Inhibitor That Reduces Atherosclerosis by Hdl Elevation and Non-hdl Reduction. Circulation. 2012; 126: A11806.
• [10] Chromanol derivatives--a novel class of CETP inhibitors. Bioorg Med Chem Lett. 2011 Jan 1;21(1):488-91.
• [11] Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic expl... Eur J Med Chem. 2010 Apr;45(4):1598-617.
• [12] Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform. Bioorg Med Chem Lett. 2009 May 1;19(9):2456-60.